Antiretroviral therapy coverage in Slovenia
Slovenia: Antiretroviral therapy coverage was 86.0% in 2024. ▲ Rising
Antiretroviral therapy coverage in Slovenia, 2000–2024
Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of people living with HIV.
Analysis
In 2024, antiretroviral therapy coverage in Slovenia stood at 86.0%. That is the highest value across all 25 years on record.
Compared with earlier readings it is up 2.4% on the previous year and up 24.6% over ten years.
Over the whole period, antiretroviral therapy coverage in Slovenia peaked at 86.0% in 2024 and was at its lowest, 27.0%, in 2000.
That places Slovenia 33rd out of 143 countries with data for 2024, putting it in the top quarter.
The long-run direction has been consistently rising across the 25 years of available data.
Antiretroviral therapy coverage in Slovenia, year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 27.0% | — |
| 2001 | 30.0% | +11.1% |
| 2002 | 32.0% | +6.7% |
| 2003 | 34.0% | +6.2% |
| 2004 | 37.0% | +8.8% |
| 2005 | 38.0% | +2.7% |
| 2006 | 52.0% | +36.8% |
| 2007 | 50.0% | -3.8% |
| 2008 | 46.0% | -8.0% |
| 2009 | 45.0% | -2.2% |
| 2010 | 60.0% | +33.3% |
| 2011 | 60.0% | +0.0% |
| 2012 | 60.0% | +0.0% |
| 2013 | 64.0% | +6.7% |
| 2014 | 69.0% | +7.8% |
| 2015 | 72.0% | +4.3% |
| 2016 | 78.0% | +8.3% |
| 2017 | 82.0% | +5.1% |
| 2018 | 83.0% | +1.2% |
| 2019 | 81.0% | -2.4% |
| 2020 | 84.0% | +3.7% |
| 2021 | 82.0% | -2.4% |
| 2022 | 83.0% | +1.2% |
| 2023 | 84.0% | +1.2% |
| 2024 | 86.0% | +2.4% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 39.1% | 27.0% | 52.0% | 10 |
| 2010s | 70.9% | 60.0% | 83.0% | 10 |
| 2020s | 83.8% | 82.0% | 86.0% | 5 |
Countries ranked near Slovenia
- 33 Azerbaijan 86.0% compare
- 33 Italy 86.0% compare
- 33 Liberia 86.0% compare
- 33 Sierra Leone 86.0% compare
- 33 Singapore 86.0% compare
More health data for Slovenia
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.8177 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,176 deaths per 1,000 people (2090)
- Number of infants who die before age 1 4 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -2.03 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.021 units per person (2025)
- Population ages 00-04, male, annual growth rate -1.58 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is antiretroviral therapy coverage in Slovenia?
- Antiretroviral therapy coverage in Slovenia was 86.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
- What is the highest antiretroviral therapy coverage recorded in Slovenia?
- The highest recorded value was 86.0% in 2024.
- What is the lowest antiretroviral therapy coverage recorded in Slovenia?
- The lowest recorded value was 27.0% in 2000.
- How does Slovenia rank for antiretroviral therapy coverage?
- Slovenia ranks 33rd out of 143 countries with data for 2024.
- Is antiretroviral therapy coverage rising or falling in Slovenia?
- Over the last ten years it is up 24.6%. The long-run trend across the full record is rising.
- Where does this Slovenia data come from?
- The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage (% of people living with HIV). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Antiretroviral therapy coverage indicates the percentage of all people living with HIV who are receiving antiretroviral therapy.